

10 May 2019

Dear Shareholder

Non-Renounceable Entitlement Offer

Analytica Limited (**Company**) today announced that it is conducting a capital raising via a non-renounceable pro-rata entitlement offer to raise up to approximately \$2.7 million (before offer costs) (**Entitlement Offer**).

Details of the Entitlement Offer

The Entitlement Offer provides you with the opportunity to subscribe for 1 new share for every 6 shares held at 7pm (Sydney time) on Wednesday, 15 May 2019 (**Record Date**) at an issue price of 0.5 cents per new share.

Eligible Shareholders

The Entitlement Offer will be offered to all shareholders of the Company with a registered address in Australia and New Zealand as at the Record Date (**Eligible Shareholders**).

The Company regrets that, having considered the number of shareholders with registered addresses outside of Australia and New Zealand (**Ineligible Shareholders**), the number and value of the shareholdings held by Ineligible Shareholders, and the costs of complying with the laws and any requirements of any regulatory authority in each applicable jurisdiction, it will not extend the Entitlement Offer to Ineligible Shareholders.

Additional Shares

Eligible Shareholders may also apply for Additional Shares (which are shares that are not taken up by Eligible Shareholders) in excess of their entitlement. The allocation of Additional Shares will be limited to the number of shortfall shares (if any) and will be at the discretion of the Directors. Eligible Shareholders who apply for Additional Shares may receive fewer Additional Shares than the number applied for or none at all.

Use of funds

The funds raised under the Entitlement Offer will be used to fund the continued development and commercialisation of the Company's PeriCoach® system and AutoStart® and AutoFlush infusion system technologies, including potential commercial discussions with prospective commercialisation partners, and working capital.

There is no minimum amount sought to be raised under the Entitlement Offer and the new shares may be issued in respect of applications irrespective of the total level of subscriptions made.

Entitlements

Entitlements in respect of new shares will be rounded down to the nearest whole number and holdings on different registers or sub-registers will not be aggregated to calculate entitlements. The Entitlement Offer is non-renounceable and entitlements cannot be traded on the ASX.



Company's capital structure pro-forma

The table below provides a pro-forma capital structure of the Company after completion of the Entitlement Offer (assuming no other shares are issued by the Company). The actual outcome of the Entitlement Offer may differ.

Share Capital	Shares
Shares currently on issue	3,337,012,350
New Shares to be issued under the Entitlement Offer	556,168,725
Potential shares on issue after the Entitlement Offer	3,893,181,075

Further information

The Entitlement Offer will be made under section 708AA of the Corporations Act. Accordingly, the Company will not prepare a prospectus or other disclosure document.

The Company has released a copy of the Entitlement Offer Booklet and the Entitlement and Acceptance Form to the ASX today, and it is available on the ASX website and the Company's website. A copy of the Entitlement Offer Booklet will also be sent to all Eligible Shareholders on Monday, 20 May 2019. Further details of the Entitlement Offer, including details on the use of proceeds and risks will be contained in the Entitlement Offer Booklet.

Important dates

Event	Date
Announcement of terms of the Entitlement Offer Entitlement Offer Booklet and acceptance form released to ASX	Friday, 10 May 2019
Existing shares quoted on an 'ex-rights' basis	Tuesday, 14 May 2019
Record Date	7pm (Sydney time) Wednesday, 15 May 2019
Entitlement Offer opens Offer Document despatched	Monday, 20 May 2019
Entitlement Offer closes	5pm (Sydney time) Friday, 31 May 2019
Announcement of shortfall (if any) under the Entitlement Offer	Wednesday, 5 June 2019
Allotment date of new shares issued under the Entitlement Offer	Friday, 7 June 2019
Despatch of holding statements for new shares issued under the Entitlement Offer. Normal trading of new shares issued under the Entitlement Offer	Tuesday, 11 June 2019



The timetable is subject to change and the Company reserves the right to withdraw or vary the timetable for the offer without notice. In particular, the Company reserves the right to extend the closing date for the Entitlement Offer, to accept late applications whether generally or in particular cases or to withdraw the Entitlement Offer without prior notice.

The Directors thank you for your ongoing support of the Company.

Yours sincerely

Dr Michael Monsour

Chairman

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

